EUCTR2016-003625-42-GB进行中（未招募）1 期
A Phase 2, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Sofosbuvir/Velpatasvir for 12 Weeks in Subjects with Chronic HCV Infection Who are on Dialysis for End Stage Renal Disease
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 59
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1) Willing and able to provide written informed consent
- •2) Male or female age = 18 years
- •3) Chronic HCV infection (= 6 months) as documented by prior medical history or liver biopsy
- •4) HCV RNA = LLOQ at screening
- •5) End stage renal disease (ESRD) requiring peritoneal dialysis (PD) or hemodialysis (HD)
- •6) The most recent HCV treatment must have been completed at least 8 weeks prior to Screening
- •7) Subjects must have a determination of treatment experience (treatment naïve vs. treatment experienced). Treatment naïve is defined as having never been exposed to an approved or experimental HCV-specific direct acting antiviral agents or prior treatment of HCV with interferon or ribavirin. All other patients will be considered treatment experienced.
- •8) Subjects must have appropriate testing for determination of cirrhosis status.
- •9) Liver imaging within 6 months of Baseline/Day 1 is required in cirrhotic subjects only to exclude hepatocellular carcinoma (HCC)
- •10) Subjects with HIV-1 coinfection may be eligible, provided they satisfy additional inclusion criteria.
- •11) A negative serum pregnancy test is required for female subjects (unless permanently sterile or greater than two years post-menopausal).
- •12) Male subjects and female subjects of childbearing potential who engage in heterosexual intercourse must agree to use protocol specified method(s) of contraception as described in Appendix 4.
- •13) Lactating females must agree to discontinue nursing before the study drug is administered.
- •14) Subject must be able to comply with the dosing instructions for study drug administration and able to complete the study schedule of assessments.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 95
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 5
排除标准
- •1) Current or prior history of any of the following:
- •a) Clinically-significant illness
- •b) Current or prior history of significant cardiac disease
- •c) Gastrointestinal disorder or postoperative condition that could interfere with the absorption of the study drug.
- •d) Difficulty with blood collection and/or poor venous access for the purposes of phlebotomy.
- •e) Clinical hepatic decompensation (i.e., ascites, encephalopathy or variceal hemorrhage).
- •f) Solid organ transplantation other than failed kidney transplants (current use of =5 mg/day of prednisone, or equivalent dose of corticosteroid, allowed).
- •g) Significant pulmonary disease
- •h) Psychiatric hospitalization, suicide attempt, and/or a period of disability as a result of their psychiatric illness within the last 2 years.
- •i) Malignancy within the 5 years prior to screening, with the exception of specific cancers that have been cured by surgical resection (basal cell skin cancer, etc). Subjects under evaluation for possible malignancy are not eligible
- •2) Screening ECG with clinically significant abnormalities
- •3) Chronic liver disease of a non-HCV etiology (e.g., hemochromatosis, Wilson’s disease, alfa 1 antitrypsin deficiency, cholangitis).
- •4) Infection with hepatitis B virus (HBV).
- •5) Opportunistic infection (reference Appendix 5) within 6 months prior to Screening
- •6) Infection (other than HIV or HCV) requiring parenteral therapy within 30 days prior to baseline.
- •7) Life threatening SAE during the screening period
- •8) Subjects has the following laboratory parameters at screening:
- •a) ALT > 10 X the upper limit of normal (ULN)
- •b) AST > 10 X ULN
- •c) Direct bilirubin > 1.5 X ULN. For subjects receiving ritonavir boosted atazanavir regimen, a direct bilirubin > 1.5 xULN will be allowed if < 25% of the total bilirubin
- •d) Platelets < 25,000/µL
- •e) HbA1c > 9%
- •f) Hemoglobin < 9 g/dL
- •g) Albumin < 2.8 g/dL
- •h) INR > 1.5 x ULN unless subject has known hemophilia or is stable on an anticoagulant regimen affecting INR
- •i) Hepatitis B surface antigen positive
- •9) Prior exposure to any HCV NS5A inhibitor.
- •10) Male with pregnant female partner.
- •11) Females who may wish to become pregnant and/or plan to undergo egg harvesting during the course of the study and up to 30 days of the last dose of study drug
- •12) Males who may wish to donate sperm during the course of the study until at least 30 days after the last dose of study drug
- •13) Clinically-relevant alcohol or drug abuse within 12 months of screening. A positive drug screen will exclude subjects unless it can be explained by a prescribed medication; the diagnosis and prescription must be approved by the investigator.
- •14) Use of any prohibited concomitant medications as described in Section 5.4.
- •15) Subjects with HIV-1 coinfection cannot be receiving an ARV regimen containing efavirenz (EFV)
- •16) Chronic use of systemically administered immunosuppressive agents (e.g., prednisone equivalent > 10 mg/day).
- •17) Known hypersensitivity to the VEL, SOF, the metabolites, or formulation excipient.
- •18) For subjects with HIV-1 coinfection only:
- •HIV-1 RNA >50 copies/mL
- •CD4 T-cell count <100 cells/mm3
- •HIV-2 positive test
研究者
相似试验
进行中（未招募）
1 期
A trial investigating the safety and efficacy of a drug combination Ledipasvir/Sofosbuvir for Subjects with hepatitis C who are on dialysis for kidney disease.Chronic Hepatitis C virus infectionMedDRA version: 19.0 Level: PT Classification code 10019744 Term: Hepatitis C System Organ Class: 10021881 - Infections and infestationsMedDRA version: 19.0 Level: PT Classification code 10008912 Term: Chronic hepatitis C System Organ Class: 10021881 - Infections and infestationsEUCTR2016-003489-25-BEGilead Sciences, Inc.100
进行中（未招募）
不适用
A Phase 2, Multicenter, Open-Label Study to Evaluate the Response to and Safety of an 8-Day Course of Phenoptin Treatment in Subjects with Phenylketonuria Who Have Elevated Phenylalanine LevelsTreatment of PhenylketonuriaMedDRA version: 6.1Level: SOCClassification code 10027433EUCTR2004-002071-16-ITBIOMARI
进行中（未招募）
1 期
A trial investigating the safety and efficacy of a drug combination Sofosbuvir/Velpatasvir for Subjects with hepatitis C who are on dialysis for kidney disease.EUCTR2016-003625-42-ESGilead Sciences, Inc.100
进行中（未招募）
1 期
A trial investigating the safety and efficacy of a drug combination Ledipasvir/Sofosbuvir for Subjects with hepatitis C who are on dialysis for kidney disease.Chronic Hepatitis C virus infectionMedDRA version: 20.1Level: PTClassification code 10008912Term: Chronic hepatitis CSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 20.0Level: PTClassification code 10019744Term: Hepatitis CSystem Organ Class: 10021881 - Infections and infestationsEUCTR2016-003489-25-ITGILEAD SCIENCES INCORPORATED95
进行中（未招募）
1 期
A clinical trial to evaluate the efficacy and safety of sofosbuvir/velpatasvir and ribavirin for 12 weeks in people with hepatitis C infection and liver scarring.Chronic hepatitis C virus infectionMedDRA version: 20.0 Level: PT Classification code 10019744 Term: Hepatitis C System Organ Class: 10021881 - Infections and infestationsMedDRA version: 20.1 Level: PT Classification code 10008912 Term: Chronic hepatitis C System Organ Class: 10021881 - Infections and infestationsEUCTR2016-003066-10-FRGilead Sciences International Ltd.32